Trials / Completed
CompletedNCT05639530
A Dose Escalation Study of IBI333 in Subjects With Neovascular Age-related Macular Degeneration
A Dose Escalation Phase I Clinical Study to Evaluate the Tolerability and Safety of IBI333 in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed for multi-center, open-label, dose escalation phase I trial to evaluate the safety and tolerability of a single and multiple intravitreal injection of IBI333 in subjects with neovascular age-related macular degeneration (nAMD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IBI333 | Intravitreal injection of IBI333 |
Timeline
- Start date
- 2023-02-27
- Primary completion
- 2023-12-07
- Completion
- 2024-04-23
- First posted
- 2022-12-06
- Last updated
- 2024-09-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05639530. Inclusion in this directory is not an endorsement.